The path forward: KCR Experts discuss what's next for technology, gene therapy and beyond

The path forward: KCR Experts discuss what's next for technology, gene therapy and beyond

Clinical research has experienced a fair deal of uncertainty in the past few years, but KCR leaders are now setting their sights on the future - illustrating how organizations can benefit from recent industry advancements to propel research forward. Through their latest written works, KCR experts Dr. Dave Li, Dr. Anna Baran, and Dr. Karoline Hahn cover a variety of topics from manufacturing to cell therapy trial design in industry publications while Chief Technology Officer, Doug Bain, breaks down the latest in clinical trial technology, based on his panel experience at last month's Veeva Summit.  

Decentralized Manufacturing: A Path towards Smart Cell and Gene Therapy Manufacturing?
Learn more about decentralized manufacturing potential and how recent advancement of continuous bioprocessing opens the doors for alternative manufacturing strategies in the latest article from KCR Senior Consultant, Dr. Karoline Hahn, published by MassBio.
 

Read here

Lilly taps Triastek to use 3D printing for gut-targeted drug delivery
Eli Lilly has identified 3D printing as a way to get drugs to specific regions of the gastrointestinal tract, leading it to team up with Triastek to work on the targeted release of molecules in the intestine. Triastek’s MED 3D printing technology enables it to apply layer upon layer of melted excipients, active pharmaceutical ingredients and blended materials. In doing so, the biotech could unlock new ways to control drug release. 
Source: Fierce Pharma

Read here

Early phase CGT trials: key design elements correlating to distinctive biological characteristics 
With increasing numbers of cell and gene therapies (CGTs) entering clinical trials, Dr. Dave Li and Dr. Anna Baran of KCR Consulting discuss how the biological characteristics of CGTs should be taken into account with early phase trial designs for the most effective and acceptable risk profiling.
 

Read here

The Key To Retention That Most Onboarding Programs Ignore 
When it comes to creating a great work experience for new employees, those first interactions on the job have a powerful and lasting impact. Making sure your newbies feel welcomed, appreciated and informed is essential to an effective entry. Overlooking these crucial steps in our era of record-low unemployment can be costly:
Source: Forbes

Read here

CRO partnering with Veeva eTMF – summary from the panel at Veeva Summit 
KCR Chief Technology Officer, Doug Bain, joined a panel at the Veeva EU R&D and Quality Summit in Zurich, Switzerland last month. He published a summary of the event, where he discusses KCR’s experience with clinical trial technology and the main takeaways from his discussion with other clinical research experts.

Read here

FDA clears wearable neurostimulator from DyAnsys to treat pain from diabetic nerve damage
In the wake of the FDA’s approval of Medtronic’s implanted spinal cord stimulators to treat pain, DyAnsys has secured an agency nod of its own for a significantly less invasive approach.The First Relief device features three small, acupuncturelike needles that reach through the skin behind the ear to access the nervous system. The FDA cleared the system for repeated treatments spanning up to eight weeks.
Source: Fierce Biotech

Read here